Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

BACKGROUND: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridizatio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Oncol
Egile Nagusiak: Kron, A, Alidousty, C, Scheffler, M, Merkelbach-Bruse, S, Seidel, D, Riedel, R, Ihle, M A, Michels, S, Nogova, L, Fassunke, J, Heydt, C, Kron, F, Ueckeroth, F, Serke, M, Krüger, S, Grohe, C, Koschel, D, Benedikter, J, Kaminsky, B, Schaaf, B, Braess, J, Sebastian, M, Kambartel, K -O, Thomas, R, Zander, T, Schultheis, A M, Büttner, R, Wolf, J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6225899/
https://ncbi.nlm.nih.gov/pubmed/30165392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy333
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak